ADMENTA UK PLC
DIRECTORS REPORT
AND FINANCIAL
STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2012

FRIDAY

A18 28/06/2013 COMPANIES HOUSE

#51

DIRECTORS REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2012

CONTENTS	PAGE
Directors' report	1
Independent auditors' report	4
Profit and loss account	6
Balance sheet	7
Notes to the financial statements	8

DIRECTORS' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2012

The directors have pleasure in presenting their annual report and the audited financial statements of the company for the year ended 31 December 2012

PRINCIPAL ACTIVITIES AND BUSINESS REVIEW

The company's principal activity during the year was to act as a holding company of a group of companies involved in the wholesaling and retailing of pharmaceutical products

The pharmaceutical wholesale and retail markets continue to be highly competitive. With the strategies adopted by the subsidiaries the directors believe the performance of and prospects of the company's investments is considered to be satisfactory. Accordingly the directors are satisfied with the result for the year and anticipate an acceptable future performance.

Principal risks and uncertainties

The key business risk to the investment activity of the company is the performance of its investments. The management of the subsidiaries and the execution of their strategies are subject to a number of key risks. Mr Tobin, Mr Beer, Mr Anderson and Mr Swift are also directors of AAH Pharmaceuticals Limited, the main trading entity of the wholesale division and Lloyds Pharmacy Limited, the main trading entity of the retail division. Risks are formally reviewed by the boards of these entities and appropriate processes are put in place to monitor and mitigate them.

The company is exposed to a variety of financial risks, which include liquidity, foreign currency and interest rate risk. The company has employed a programme that seeks to manage and limit any adverse effects of these risks on the financial performance of the company, which are described in more detail below

The directors have not delegated the responsibility of monitoring financial risk management to a sub-committee of the board, although use is made of a central treasury function which arranges the overall funding requirements of the Admenta UK Plc group. This central function operates within a framework of clearly defined policies and procedures which have been approved by the directors, and reports to the board on a monthly basis. The policies approved by the board of directors are implemented by the company's finance department and the central treasury function. The policies cover funding and hedging instruments, exposure limits and a system of authority for the approval and execution of transactions.

Liquidity risk the company participates in the banking arrangements of the UK group, which are arranged with the assistance of the central treasury function. The UK group funds its operations through a mix of retained earnings, borrowings and leasing that is designed to ensure that the company has sufficient funds for its day to day operations and other activities. Cash flow requirements are monitored through rolling projections which are compiled across the group.

DIRECTORS' REPORT (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

Foreign currency and interest rate risk the subsidiaries affected by foreign currency risk use instruments to manage this risk. The company also has both interest bearing assets and liabilities, these being managed within the UK group

Key performance indicators (KPIs)

Given the straightforward nature of the business, the company's directors are of the opinion that analysis using KPIs is not necessary for an understanding of the development, performance or position of the business

Treasury risk management

The company has used derivatives within its borrowing agreements to manage interest rate risk arising from its sources of finance. It is, and has been throughout the year, the company's policy that no trading in financial instruments shall be undertaken

The main risks arising from the company's financial instruments are interest rate risk, liquidity risk and credit risk. The group treasury committee reviews and agrees the management of these risks

RESULTS AND DIVIDENDS

The profit for the year amounted to £146,684,000 (2011 profit of £79,331,000) Particulars of dividends paid are detailed in note 9 to the financial statements

DIRECTORS

The directors who served the company during the year and up to the date of this report are as follows

(Resigned 28 February 2013)
(Appointed 1 March 2013)
(Appointed 1 April 2013)
(Appointed 22 March 2012)
(Resigned 25 June 2012)
(Resigned 24 January 2012)
(Resigned 25 June 2012)

QUALIFYING THIRD PARTY INDEMNITY PROVISIONS

Liability insurance, a qualifying third party indemnity provision for the purposes of the Companies Act 2006 is provided for the UK directors by Franz Haniel & Cie GmbH, the ultimate controlling party. This was in force during the year and also on the date of approval or the financial statements.

DIRECTORS' REPORT (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations

Company law requires the directors to prepare financial statements for each financial year Under that law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law) Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period In preparing those financial statements, the directors are required to

- select suitable accounting policies and then apply them consistently,
- make judgements and accounting estimates that are reasonable and prudent,
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements,
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT OF DISCLOSURE OF INFORMATION TO AUDITORS

In the case of each director in office at the date the directors' report is approved under Section 418 of the Companies Act 2006, the following applies

- In so far as the directors are aware, there is no relevant audit information of which the company's auditor is unaware, and
- they have taken all steps that they ought to have taken as directors in order to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information

On behalf of the board

T Beer Director

Approved by the directors on 29 May 2013

Thortee for

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ADMENTA UK PLC

We have audited the financial statements of Admenta UK plc for the year ended 31 December 2012 which comprise the Profit and Loss Account, Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice)

RESPECTIVE RESPONSIBILITIES OF DIRECTORS AND AUDITORS

As explained more fully in the Statement of Directors' Responsibilities set out on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland) Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors

This report, including the opinions, has been prepared for and only for the company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing

SCOPE OF THE AUDIT OF THE FINANCIAL STATEMENTS

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed, the reasonableness of significant accounting estimates made by the directors, and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the directors' report to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

OPINION ON FINANCIAL STATEMENTS

In our opinion the financial statements

- give a true and fair view of the state of the company's affairs as at 31 December 2012 and of its profit for the year then ended,
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, and
- have been prepared in accordance with the requirements of the Companies Act 2006

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ADMENTA UK PLC (continued)

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us, or
- the financial statements are not in agreement with the accounting records and returns, or
- certain disclosures of directors' remuneration specified by law are not made, or
- we have not received all the information and explanations we require for our audit

Mike Robinson (Senior Statutory Auditor)

For and on behalf of

PricewaterhouseCoopers LLP

Chartered Accountants & Statutory Auditors

Milton Keynes

5

PROFIT AND LOSS ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2012

TURNOVER	Note	2012 £000	2011 £000
Administrative expenses		(3)	(64)
OPERATING LOSS	2	(3)	(64)
Income from shares in group undertakings Interest receivable and similar income Interest payable and similar charges	5 6 7	180,000 4,959 (49,083)	120,000 5,055 (60,323)
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION	_	135,873	64,668
Tax on profit on ordinary activities	8	10,811	14,663
PROFIT FOR THE FINANCIAL YEAR	17	146,684	79,331

All of the activities of the company are classed as continuing

The company has no recognised gains or losses other than the results for the year as set out above and therefore no separate statement of total recognised gains and losses has been prepared

There is no material difference between the results above and the results on an unmodified historical cost basis

BALANCE SHEET

31 DECEMBER 2012

	Note	000£	2012 £000	2011 £000
FIXED ASSETS Investments	10		1,303,100	1,303,100
CURRENT ASSETS Debtors	11	4,462		6,968
CREDITORS: Amounts falling due within one year	12	(903,124)		(892,314)
NET CURRENT LIABILITIES			(898,662)	(885,346)
TOTAL ASSETS LESS CURRENT LIABILITIE	es		404,438	417,754
CAPITAL AND RESERVES Called up share capital Profit and loss account	16 17		400,050 4,388	400,050 17,704
TOTAL SHAREHOLDERS' FUNDS	18		404,438	417,754

These financial statements on pages 6 to 18 were approved by the board of directors and authorised for issue on 29 May 2013, and were signed on its behalf by

T Beer Director

Company Registration Number 03011757

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2012

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with applicable accounting standards in the United Kingdom and the Companies Act 2006

Set out below is a summary of the more important accounting policies, which have been applied consistently except where stated otherwise

Going concern

The company relies on its parent company, Celesio AG, for financial support. The financial statements of Admenta UK Plc have been prepared on the going concern basis which assumes that the company will continue in existence for the foreseeable future. A facility of £700m (2011 £700m) is made available to Admenta UK Plc by another group company, Celesio Finance B V. The parent company continues to instruct Celesio B V. to provide this on-going support and the directors have received written confirmation from the directors of Celesio Finance B V. that this support remains in place.

Consolidated financial statements

The financial statements contain information about Admenta UK Plc as an individual company, rather than consolidated information as the parent of the group. The company is exempt under section 400 of the Companies Act 2006 from the requirement to prepare group financial statements as its results are included by full consolidation in the financial statements of its ultimate parent, Franz Haniel & Cie GmbH, a company incorporated in Germany

Cash flow statement

The directors have taken advantage of the exemption in Financial Reporting Standard No 1 (Revised 1996) - "Cash flow statements" from including a cash flow statement in the financial statements on the grounds that the company is wholly owned and its parent publishes a consolidated cash flow statement

Swap agreements

Interest adjustments receivable or payable under interest rate swap agreements are credited or charged to the profit and loss account for the period of account in which they accrue Other amounts receivable or payable in connection with such agreements are also credited or charged to the profit or loss account on an accruals basis, being an apportionment of the amount received or paid, over the remaining term of the company's rights or obligations under the agreement

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

1. ACCOUNTING POLICIES (continued)

Taxation

The charge for taxation is based on the result for the year and takes into account taxation deferred because of timing differences between the treatment of certain items for accounting and taxation purposes. Deferred tax liabilities are provided in full but deferred tax assets are recognised only to the extent it is considered more likely than not that the associated tax deduction can be utilised on their reversal. Deferred tax liabilities and assets are not discounted

Pension costs and other post-retirement benefits

The company operates several pension schemes, one of which is a defined benefit and two defined contribution. All schemes are funded and constituted as independently administered funds with their assets being held separately from those of the company. The net liabilities under the defined benefit pension scheme are included in the balance sheets of Lloyds Pharmacy. Limited and AAH Pharmaceuticals Limited. The expected return on pension scheme assets and interest costs are included within net finance income and actuarial gains and losses are included within the statement of total recognised gains and losses of Lloyds Pharmacy Limited and AAH Pharmaceuticals Limited.

Investments

Shares in group companies are shown at historic cost less any necessary write down for impairment. The basis for any impairment is by reference to the net asset value of the investment.

Financial instruments

The company has adopted the presentation requirements of FRS 25 - "Financial instruments disclosure and presentation" and the disclosure requirements on financial instruments in the Companies Act 2006 Financial instruments are treated as equity instruments if the instrument includes no contractual obligations to deliver cash or another financial asset to another entity or to exchange financial liabilities with another entity under conditions that are potentially unfavourable to the issuer All other financial instruments are treated as financial liabilities

2. OPERATING LOSS

Operating loss is stated after charging

	2012	2011
	£000	£000
Auditors' remuneration		
- Audit of company	_	-
_ , , , , , , , , , , , , , , , , , , ,		

Auditors' remuneration of £4,000 (2011 £4,000) has been borne by Lloyds Pharmacy Limited, a fellow group company and not recharged No non-audit services have been provided by the auditors during the year (2011 £nil)

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

3. DIRECTORS' EMOLUMENTS

The emoluments of Mr Page, Mr Shepherd and Mr Willetts were paid by a fellow group company, Lloyds Pharmacy Limited, which makes no recharge to the company Mr Page, Mr Shepherd and Mr Willetts were directors of a number of fellow group companies and it is not possible to make an accurate apportionment of their emoluments in respect of each of these companies Accordingly no emoluments in respect of these directors are disclosed The directors' emoluments are included in the aggregate of the directors' emoluments disclosed in the financial statements of Lloyds Pharmacy Limited

The emoluments of Mr James were, and those of Mr Beer and Mr Anderson are, paid by a fellow group company, AAH Pharmaceuticals Limited, which makes no recharge to the company Mr James was, and Mr Beer and Mr Anderson are, directors of a number of fellow group companies and it is not possible to make an accurate apportionment of their emoluments in respect of each of these companies Accordingly no emoluments in respect of these directors are disclosed. The directors' emoluments are included in the aggregate of the directors' emoluments disclosed in the financial statements of AAH Pharmaceuticals Limited.

4. PARTICULARS OF EMPLOYEES

The company had no employees during the year, other than executive directors (2011 - none)

2011

5. INCOME FROM SHARES IN GROUP UNDERTAKINGS

		2012 £000	2011 £000
	Income from group undertakings	180,000	120,000
6.	INTEREST RECEIVABLE AND SIMILAR INCOME		
		2012	2011
		£000	£000
	Interest from group undertakings	4,959	5,055
7.	INTEREST PAYABLE AND SIMILAR CHARGES		
		2012	2011
		£000	£000
	Group interest payable	40,360	34,659
	Other similar charges	8,723	25,664
		49,083	60,323

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

8. TAX ON PROFIT ON ORDINARY ACTIVITIES

(a) Analysis of credit in the year

	2012	2011
	£000	£000
Current tax		
UK Corporation tax based on the results for the year at 24 50%		
(2011 26 50%)	(10,811)	(14,663)
Total current tax credit	(10,811)	(14,663)

(b) Factors affecting current tax charge

The tax assessed on the profit on ordinary activities for the year is lower (2011 lower) than the standard rate of corporation tax in the UK of 24 50% (2011 26 50%) The differences are explained below

Profit on ordinary activities before taxation	2012 £000 135,873	2011 £000 64,668
Profit on ordinary activities before taxation multiplied by the standard rate of tax of 24 5% (2011 26 5%)	33,289	17,137
Effects of Income not subject to tax	(44,100)	(31,800)
Total current tax credit (note 8(a))	(10,811)	(14,663)

(c) Changes to the UK corporation tax system

The standard rate of corporation tax in the UK reduced from 26% to 24% with effect from 1 April 2012 Accordingly the company's profits for this accounting period are taxed at an effective rate of 24 5%

Finance Act 2012 also included legislation to reduce the main rate of corporation tax to 23% from 1 April 2013. As these changes were substantively enacted at the balance sheet date, the deferred tax balance has been restated to reflect the reduced rate of 23%

In addition to the changes in rates of corporation tax disclosed above, further changes to the UK corporation tax rates were announced in the 2012 Autumn Statement and the March 2013 Budget These include further reductions to the main rate to reduce the rate to 21% from 1 April 2014 and to 20% from 1 April 2015 These changes had not been substantively enacted at the balance sheet date and, therefore, are not included in these financial statements

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

9. DIVIDENDS

	2012 £000	2011 £000
Paid during the year Interim paid 2012 £0 40 per share (2011 £0 30 per share)	160,000	120,000

10. INVESTMENTS

COST	£000
At 1 January 2012 and 31 December 2012	1,303,100
NET BOOK VALUE At 31 December 2012 and 31 December 2011	1,303,100
THE DECEMBER 2012 AND OF DOCUMENT 2011	1,000,100

The principal subsidiary companies are listed below

Subsidiary	Country of Registration	1 Class of capital	% held
AAH Limited	England and Wales	25p ordinary shares	100
Lloyds Chemists Limited	England and Wales	5p ordinary shares	100
AAH Twenty Six Limited	England and Wales	£1 ordinary shares	100
AAH Twenty Seven Limited	England and Wales	£1 ordinary shares	100
Celesio Manufacturer Solutions UK			
Distributors Limited	England and Wales	£1 ordinary shares	100

The principal activity of AAH Limited during the year was to act as a holding company of various subsidiaries. The principal activities of these subsidiaries is the wholesale of pharmaceutical products and the operation of retail pharmacies.

The principal activity of Lloyds Chemists Limited during the year was to act as a holding company of various dormant companies

AAH Twenty Six Limited, AAH Twenty Seven Limited and Celesio Manufacturer Solutions UK Distributors Limited were dormant throughout the year

The directors consider that the aggregate value of the company's shares in its group undertakings is not less than the aggregate of the amounts at which its shares are included in the company's balance sheet

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

11.	DEBTORS		
		2012 £000	2011 £000
	Corporation tax receivable	4,462	6,968
		4,462	6,968
12.	CREDITORS: Amounts falling due within one year		
		2012	2011
		£000	£000
	Bank overdrafts	1	_
	Amounts owed to group undertakings	902,144	891,327
	Accruals and deferred income	979	987
		903,124	892,314

Bank overdrafts are secured by an inter-company composite guarantee

The gross amount owed to group undertakings of £1,313,252,000 (2011 £1,253,683,000) is offset by £411,108,000 (2011 £362,356,000) of loans due from these group undertakings where there is a right of offset, giving net amounts owed to group undertakings of £902,144,000 (2011 £891,327,000) Of the gross amounts owed to group undertakings £236,427,000 (2011 £236,606,000) is due on demand and represents interest free loans, £455,290,000 (2011 £475,414,000) is repayable within one month and attracts interest based on market rates. The remaining balance represents loans on a revolving credit facility of up to five years which can be repaid upon request by Admenta UK Plc and attract interest based on market rates.

13. DERIVATIVES

Admenta UK Plc has three interest rate swaps (five in 2011) with remaining terms ranging between 3 months and 6 years. The swaps cover a total borrowing of £160m (2011 £210m), where the difference between the fixed rate and the 6 month LIBOR generates a payment or receipt to Admenta UK Plc For 2012 this totalled a payment of £8,723,000 (2011 payment £25,664,000)

14. DEFERRED TAXATION

The company had no liability for deferred taxation at 31 December 2012 (2011 - £nil)

15. RELATED PARTY TRANSACTIONS

The company has not disclosed transactions with fellow group companies which are 100% owned, in accordance with the exemption under the terms of Financial Reporting Standard 8 - "Related party disclosures"

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

16.	CALLED UP SHARE CAPITAL					
	Allotted, called up and fully paid:					
		2012		2011		
		No	£000	No	£000	
	Ordinary shares of £1 each	400,050,000	400,050	400,050,000	400,050	
17.	PROFIT AND LOSS ACCOUNT					
					2012	
					£000	
	Balance brought forward				17,704	
	Profit for the financial year				146,684	
	Dividends paid (note 9)				(160,000)	
	Balance carried forward				4,388	
18.	RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS					
				2012	2011	
				£000	£000	
	Profit for the financial year			146,684	79,331	
	Dividends paid (note 9)			(160,000)	(120,000)	
	Net reduction to shareholders' funds			(13,316)	(40,669)	
	Opening shareholders' funds			417,754	458,423	
	Closing shareholders' funds			404,438	417,754	

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

19. PENSIONS AND OTHER POST-RETIREMENT BENEFITS

The company operates a defined benefit pension scheme in the UK which covers a small number of the Admenta UK plc subsidiary employees. The full disclosure of the pension obligations is shown below with the specific FRS17 - "Retirement benefits" deficit allocation reflected in the financial statements of Lloyds Pharmacy Limited and AAH Pharmaceuticals Limited. The balances are not reflected in these financial statements but are disclosed in the individual entity's financial statements as appropriate. An actuarial valuation was carried out as at 6 April 2011 and updated to 31 December 2012 by a qualified independent actuary.

The major assumptions used by the actuar	y were
--	--------

, ,	2012	2011	2010
	%	%	%
Discount rate	4.30	4 70	5 40
Inflation assumption	2.80	2 80	3 40
Rate of increase in salaries	3.80	3 80	4 40
Expected return on scheme assets	4.90	4 99	5 57
Pension increases linked to price inflation subject to a			
maximum of 5% p a	2.80	2 70	3 30
The assumed life expectancies on retirement at age 65 are			
Current pensioners			
Male aged 65	87.7	87 2	86 6
Female aged 65	89.5	88 1	89 0
Future pensioners			
Male aged 45	88.7	89 0	88 5
Female aged 45	89.8	90 7	90 8

The scheme has a range of different pension increases for different benefit categories, not all of which are detailed above Further details of the various rates of pension increases can be found in the scheme documentation

The group contributions during the year amounted to £11,348,000 (2011 £11,080,000) and the agreed company contribution rate for the coming year is 21 4% pa of pensionable salaries plus £10,161,000 (2011 18 2% pa of pensionable salaries plus £10,161,000) The estimated contribution to be paid to the scheme by the company next year is £11,233,000 Expenses and levies to the Pension Protection Fund are included in these contributions

The scheme is closed to new entrants so the average age of the membership is expected to increase over time. The projected unit method is used to calculate the current service cost. This calculates the value of the following years' pension accrual and expresses it as a percentage of pensionable pay. This percentage increases as the members of the scheme approach retirement.

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

19. PENSIONS AND OTHER POST-RETIREMENT BENEFITS (continued)

The fair value of the scheme assets, the present value of the scheme liabilities and the resulting deficit are

	2012	2011	2010
	£000	£000	£000
Equities	31,496	27,970	25,418
Bonds	132,545	115,855	109,785
Property	8,873	7,876	7,377
Absolute return fund	27,984	24,396	23,173
Others	3,019	3,163	3,664
Total market value of assets	203,917	179,260	169,417
Present value of funded scheme liabilities	(222,738)	(211,061)	(197,091)
Deficit in the scheme	(18,821)	(31,801)	(27,674)
Related deferred tax asset	4,329	9,950	7,472
Net pension liability	(14,492)	(21,851)	(20,202)

There are no company related investments included in the fair value of assets

The overall expected return on assets is calculated as the weighted average of the expected returns on each individual asset class. The expected returns for each asset class have been set with reference to market yields and include an allowance for expenses.

The actual return on scheme assets are

	2012	2011
	£000	£000
Actual return on scheme assets	23,095	8,050
Reconciliation of the present value of the scheme liabilities is shown below	ow .	
	2012	2011
	£000	£000
At 1 January	211,061	197,091
Service cost	1,014	1,123
Interest cost	9,714	10,643
Members' contributions	135	148
Actuarial loss on scheme liabilities	10,735	11,491
Benefits paid	(9,921)	(9,435)
At 31 December	222,738	211,061

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

19. PENSIONS AND OTHER POST-RETIREMENT BENEFITS (continued)

Reconciliation of the fair value of scheme assets is shown below		
	2012 £000	2011 £000
At 1 January Expected return on scheme assets Actuarial gain/(loss) on scheme assets Contributions by the company Members' contributions Benefits paid At 31 December	179,260 8,984 14,111 11,348 135 (9,921) 203,917	169,417 9,486 (1,436) 11,080 148 (9,435) 179,260
The amounts recognised in the profit and loss account are as follows	<u> </u>	
The amounts recognised in the profit and rose account are as rose we	2012 £000	2011 £000
Current service cost Interest cost Expected return on pension scheme assets	1,014 9,714 (8,984)	1,123 10,643 (9,486)
Total charge	1,744	2,280
The amounts recognised in the statement of total recognised gains and Lloyds Pharmacy Limited and AAH Pharmaceuticals Limited are as follows:		GL) within
	2012 £000	2011 £000
Actuarial gain/(loss) Effect of the limit on the net asset to be recognised	3,376	(12,927)
Actuarial gain/(loss) recognised in STRGL	3,376	(12,927)
Cumulative loss recognised in STRGL	(39,986)	(43,362)

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE YEAR ENDED 31 DECEMBER 2012

19. PENSIONS AND OTHER POST-RETIREMENT BENEFITS (continued)

A history of assets, liabilities and actuarial gains and losses is shown below

	2012 £000	2011 £000	2010 £000	2009 £000	2008 £000
Present value of scheme liabilities (£000) Fair value of scheme assets (£000)	(222,738) 203,917	(211,061) 179,260	(197,091) 169,417	(186,186) 151,114	(163,430) 137,676
Deficit (£000)	(18,821)	(31,801)	(27,674)	(35,072)	(25,754)
Difference between the expected and actual return on scheme assets - amount $(£000)$ 14,111 $(1,436)$ 9,091 11,262 $(40, -\%)$ of scheme assets 7 (1) 5 7					(40,117) (29)
Experience profits/(losses) on scheme - amount (£000) - % of the present value of scheme	liabilities (222)	1,064	(1,433)	1,951	(1,039)
liabilities	-	1	(1)	1	(1)

The values of the assets have been taken at bid value

20. ULTIMATE PARENT UNDERTAKING AND CONTROLLING PARTY

The immediate parent undertaking is Celesio AG, a company registered in Germany The company's ultimate parent undertaking and controlling party is Franz Haniel & Cie GmbH, a company registered in Germany, by virtue of its majority shareholding in the intermediate parent Celesio AG and its consolidation of the Celesio AG Group results into its own consolidated financial statements

Consolidated financial statements for the largest group of undertakings are prepared by Franz Haniel & Cie GmbH and may be obtained from Franz Haniel Platz 1, D-47119 Duisburg, Ruhrort, Germany

Consolidated financial statements for the smallest group of companies are prepared by Celesio AG and may be obtained from Celesio AG, Neckartalstrasse 155, D-70376 Stuttgart, Germany